Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone?

Tezel, Nihal; Taşdelen, Özlem Yılmaz; Bodur, Hatice; Gül, Ülker; Çakmak, Seray Külcü; Oğuz, İşıl Deniz; Karabulut, Erdem

doi:10.1111/1756-185x.12283

Cited by 29 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of AS ranges from 0.02% to 0.35% worldwide, whereas the prevalence of PsA ranges from 0.01% to 0.19% [3] and can be up to approximately 40% in patients with psoriasis [2]. Both conditions negatively affect quality of life, physical and social functioning, and work productivity, in addition to being associated with comorbidities and increased mortality [4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

Garrido‐Cumbrera

Hillmann²,

Mahapatra

et al. 2017

Rheumatol Ther

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are both chronic, inflammatory conditions that result in a substantial burden of disease and reduced quality of life for patients. Patient involvement in developing optimal disease management strategies, including defining appropriate goals, therapies, and treatment options, as well as in setting policy priorities and agendas, is key. A working group of patient organization representatives and rheumatologists explored what patients consider to be unmet needs, important treatment gaps, and future priorities in PsA and AxSpA management. Reducing pain and fatigue, and improving physical and social functioning and work productivity were identified as important treatment goals for patients. Although the major treatment target for both PsA and AxSpA is remission, with low/minimal disease activity an alternative target for patients with established or long-standing disease, the meaning of remission from the patient’s perspective needs to be explored further as it may differ considerably from the physician’s perspective. Key recommendations from the working group to tackle unmet needs included reducing time to diagnosis, increasing patient and physician disease awareness, focusing on patients’ priorities for treatment goals, and improving patient–physician communication. By addressing these key action points moving forward, the hope is that outcomes will continue to improve for patients with PsA and AxSpA.

show abstract

Section: Introductionmentioning

confidence: 99%

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

Garrido‐Cumbrera

Hillmann²,

Mahapatra

et al. 2017

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

“…Tezel et al28 studied 80 patients with PA, 40 patients with Ps and 40 healthy subjects in terms of QoL and functional status and found that patients with Ps and PA had worse QoL and patients with PA had worse functional status than healthy individuals.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis

Carneiro¹,

Chaves

Verardino

et al. 2017

CCID

View full text Add to dashboard Cite

BackgroundPsoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue.ObjectivesThis study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity.Patients and methodsThis cross-sectional study was performed on outpatients with psoriatic arthritis. Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F; version 4) was used to measure fatigue; 36-Item Short Form Health Survey (SF-36) and Psoriasis Disability Index (PDI) to measure quality of life; Health Assessment Questionnaire (HAQ) to assess functional capacity; Hospital Anxiety and Depression (HAD) scale to measure anxiety and depression symptoms; Psoriasis Area and Severity Index (PASI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI) to evaluate clinical activity.ResultsIn all, 101 patients with mean age of 50.77 years were included. The mean PDI score was 8.01; PASI score, 9.88; BASDAI score, 3.59; HAQ score, 0.85; HAD – Anxiety (HAD A) score, 7.39; HAD Depression (HAD D) score, 5.93; FACIT–Fatigue Scale (FACIT-FS) score, 38.3 and CDAI score, 2.65. FACIT-FS was statistically associated with PASI (rs −0.345, p<0.001), PDI (rs −0.299, p<0.002), HAQ (rs −0.460, p<0.001), HAD A (rs −0.306, p=0.002) and HAD D (rs −0.339, p<0.001). The correlations with CDAI and BASDAI were not confirmed. There was statistically significant correlation with all of the domains of SF-36 and FACIT-F (version 4).ConclusionPrevalence of fatigue was moderate to intense in <25% of patients with psoriatic arthritis. Fatigue seems to be more related to the emotional and social aspects of the disease than to joint inflammatory aspects, confirming that the disease’s visibility is the most disturbing aspect for the patient and that “skin pain” is more intense than the joint pain.

show abstract

“…15,16 HRQoL is an important outcome for daily practice and evidence based data; however, to our knowledge, limited number of publications are present regarding PsQoL questionnaires in PsA. [16][17][18][19] PsQoL questions social, psychological, and occupational issues but not physical functions. 17 Some authors pointed out that the questionnaire for PsQoL is not adequate for the evaluation of HRQoL of patients with PsA because this questionnaire does not include questions on basic dermatological clinical picture.…”

mentioning

confidence: 99%

“…[16][17][18][19] PsQoL questions social, psychological, and occupational issues but not physical functions. 17 Some authors pointed out that the questionnaire for PsQoL is not adequate for the evaluation of HRQoL of patients with PsA because this questionnaire does not include questions on basic dermatological clinical picture. 16,17,20 VITACORA-19 (psoriatic arthritis quality of life questionnaire) is the second diseasespecific patient reported outcome measurement tool to assess HRQoL in patients with PsA.…”

mentioning

confidence: 99%

Reliability and Validity of the Turkish Adaptation of VITACORA-19 in Patients with Psoriatic Arthritis

et al. 2016

View full text Add to dashboard Cite

Objectives: This study aims to evaluate the reliability and validity of the Turkish language version of VITACORA-19 (psoriatic arthritis quality of life questionnaire) in patients with psoriatic arthritis. Patients and methods:The Turkish version of VITACORA-19 questionnaire was obtained after a translation and back translation process. The study sample included 61 PsA patients (22 males, 39 females; mean age 46.5±12.2 years; range 19 to 71 years). To assess the test-retest reliability of the Turkish VITACORA-19, the questionnaire was reapplied 10 to 15 days after the first interview (interclass correlation coefficient). Cronbach's alpha (a) was used to evaluate the internal consistency. VITACORA-19 was compared with visual analog scale for physician and patient global assessments, the Health Assessment Questionnaire, and Nottingham Health Profile for construct validity. The internal structure of VITACORA-19 was examined by factor analysis. Results: The individual item intraclass correlation coefficient ranged from 0.77 to 0.98 and Cronbach's alpha ranged from 0.77 to 0.98. The Cronbach's alpha value for whole scale was determined as 0.96. The Kaiser-Meyer-Olkin measure of sampling adequacy was 0.90, and Bartlett's test of sphericity had a p<0.001. Turkish VITACORA-19 total scores were correlated negatively with Health Assessment Questionnaire, visual analog scale for pain, and Nottingham Health Profile subgroups, and positively with physician and patient global assessments (p<0.01). Conclusion: Turkish version of VITACORA-19 questionnaire is a reliable and valid measure for health-related quality of life in Turkish patients with psoriatic arthritis.

show abstract

Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone?

Cited by 29 publications

References 24 publications

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis

Reliability and Validity of the Turkish Adaptation of VITACORA-19 in Patients with Psoriatic Arthritis

Contact Info

Product

Resources

About